Learn more →
Back to Expert Scholars
Translational Medicine / 转化医学Biomarker-Driven Lung Cancer Therapy

Mark Awad

MD, PhD

🏢Dana-Farber Cancer Institute🌐USA

Clinical Director, Lowe Center for Thoracic Oncology

47
h-index
0
Key Papers
0
Key Contributions

👥Biography 个人简介

Dr. Mark Awad is a translational oncologist known for his work integrating molecular biomarkers with immunotherapy decision-making in lung cancer. He has investigated why oncogene-driven lung cancers (EGFR, ALK) respond poorly to checkpoint inhibitors and characterized the immune microenvironment in these subtypes. His research has guided biomarker-based treatment algorithms for NSCLC patients.

Share:

🧪Research Fields 研究领域

ALK/ROS1 fusions
IO in driver-mutant NSCLC
liquid biopsy monitoring
co-mutation analysis
TME in lung cancer

🎓Key Contributions 主要贡献

Representative Works 代表性著作

📄Data Sources 数据来源

Last updated: 2026-03-01 | All information from publicly available academic sources

关注 Mark Awad 的研究动态

Follow Mark Awad's research updates

留下邮箱,当我们发布与 Mark Awad(Dana-Farber Cancer Institute)相关的新研究或访谈时,我们会通知你。

我们不会泄露你的信息,也不会发送无关内容。随时可以退订。

Explore More Experts

Discover the researchers shaping the future of cancer treatment